Literature DB >> 2872059

Comparative study of the respiratory effects of two beta 1-selective blocking agents atenolol and bevantolol in asthmatic patients.

F Philip-Joet, A Saadjian, B Bruguerolle, A Arnaud.   

Abstract

Seven asthmatic patients were given a single placebo tablet in a first test session and then in two subsequent double blind sessions they randomly received 400 mg bevantolol or 100 mg atenolol, with at least 2 days between each of the sessions. Neither beta-blocker had any significant effect on FVC as compared to the placebo. FEV 1, however, was significantly lower 2 and 3 h after atenolol or bevantolol; there was no significant difference between the effects of the two drugs on FEV 1. Peak expiratory flow rate was reduced by bevantolol but not by atenolol, the difference reaching significance after 3 h. Fenoterol inhalation at the end of each test session always enhanced pulmonary performance, but to a lesser extent after bevantolol than after placebo or atenolol. A slower heart rate was recorded 2, 3, and 4 h after bevantolol and 3 and 4 h after atenolol; the mean 2-h value was significantly lower with atenolol than with bevantolol. No patient suffered any adverse effect. Bevantolol may be slightly less selective than atenolol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872059     DOI: 10.1007/bf00614188

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Beta-blockers and asthma.

Authors:  P B Decalmer; S S Chatterjee; J M Cruickshank; M K Benson; G M Sterling
Journal:  Br Heart J       Date:  1978-02

Review 2.  Intrinsic sympathomimetic activity: clinical fact or fiction?

Authors:  S H Taylor
Journal:  Am J Cardiol       Date:  1983-11-10       Impact factor: 2.778

3.  Comparison of the beta 1 and beta 2 adrenoceptor blocking properties of acebutolol and propranolol.

Authors:  T L Whitsett; D C Levin; C V Manion
Journal:  Chest       Date:  1982-12       Impact factor: 9.410

4.  Assessment of bronchial beta blockade after oral bevantolol.

Authors:  A D Mackay; H R Gribbin; C J Baldwin; A E Tattersfield
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

5.  Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways.

Authors:  D Patakas; V Argiropoulou; G Louridas; V Tsara
Journal:  Thorax       Date:  1983-02       Impact factor: 9.139

6.  Influence of intrinsic sympathomimetic activity (ISA) during beta-adrenoceptor blockade in asthmatics.

Authors:  P Dorow
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

7.  Assessment of beta-adrenoceptor antagonists in asthmatic patients.

Authors:  R E Ruffin; E L McIntyre; K M Latimer; H E Ward; A J Crockett; J H Alpers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

8.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

9.  Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

10.  beta-Adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease.

Authors:  C L van Herwaarden
Journal:  J Cardiovasc Pharmacol       Date:  1983       Impact factor: 3.105

View more
  1 in total

Review 1.  Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.

Authors:  Jillian G Baker; Stephen J Hill; Roger J Summers
Journal:  Trends Pharmacol Sci       Date:  2011-03-21       Impact factor: 14.819

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.